Hendrix Genetics will continue to conduct its business under its current corporate governance and with its existing management team, strategy and structure. Its Vision 2020 plan, created last year, identified many opportunities to invest in R&D, capacity expansion and acquisitions to continue the company’s impressive growth of the last decade. The equity of NPM/SHV will enable Hendrix Genetics to accelerate the execution of its ambitious plan.
Antoon van den Berg, CEO, Co-Shareholder and Co-Founder of Hendrix Genetics commented: “We are privileged as the Management Team of Hendrix Genetics, to have shareholders that fully support the accelerated execution of our ambitions. The fact that we continue to be family-controlled ensures passion and quick decision-making, which is essential to our company’s future.”
Jeroen Drost, CEO of NPM Capital, stated: “We discovered in Hendrix Genetics an ambitious company with dedicated shareholders, capable management and an excellent track-record in building a sound platform for industry consolidation. Their mission to help the world meet the growing demand for food, making animal protein production more efficient, affordable and sustainable perfectly fits our company ethos.”
Thijs Hendrix, president and controlling shareholder of Hendrix Genetics, commented: “Together we have created a new platform with a new horizon”.
International Advisory Board
Michel Boucly, member of the International Advisory Board since 2008, will step down per July 1, 2015 and will be succeeded by Cyril Melin, Investment Director of Sofiprotéol.
New member of the International Advisory Board, Investment Director of NPM Capital, Johan Terpstra sees clear benefits: “The strategic and cultural fit of Hendrix Genetics with NPM/SHV was clear from the onset and we look forward to partnering with existing shareholders and management to assist the growth of Hendrix Genetics in the years to come.”
